Syros appoints Peter Wirth as chairman
Mr. Wirth was a senior executive at Genzyme from 1996 until its acquisition by Sanofi in 2011, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary.
During his time at Genzyme, Mr. Wirth had senior management responsibility for the company’s legal function, corporate development function, molecular oncology division, polymer drug discovery and development division and enterprise risk management function.
Prior to Genzyme, Mr. Wirth practiced law at Palmer & Dodge LLP, where he was head of the firm’s biotechnology practice group and served as outside counsel for Genzyme as well as numerous other biopharmaceutical companies.
Mr. Wirth is currently Chairman of FORMA Therapeutics, a small molecule drug discovery company, Executive Chairman of ZappRx, a digital health company, and Senior Advisor to Zai Lab Limited, a Shanghai-based biopharmaceutical company.
Mr. Wirth was a 2012 Advanced Leadership Fellow at Harvard University. He received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School. ■
LATEST MOVES FROM Massachusetts
- PTC appoints Corinna Lathan to board
- J.Jill appoints James S. Scully to board
- Raytheon elects Robert O. Work as director
- Xenetic Biosciences appoints three directors
- Insulet appoints two to board
More inside POST